DGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Quest Diagnostics (DGX) is not a strong buy right now for a beginner with a long-term focus, but it is a reasonable hold/watch. The stock has good fundamental support from a solid Q1 beat, multiple analyst price target increases, and strong hedge fund accumulation, yet the technical setup is stretched and options sentiment is mixed. Since the investor is impatient and does not want to wait for a perfect entry, I would still not call this a clear buy today because upside looks more limited near current levels after the recent run-up.
DGX is in a bullish intermediate trend: SMA_5 is above SMA_20, and SMA_20 is above SMA_200, which confirms upward momentum. The MACD histogram is positive and expanding, supporting continuation. However, RSI_6 is 80.774, which is deeply overbought and suggests the stock is extended in the short term. Price at 215.72 is sitting just above the first resistance area around R1 214.847, with the next resistance near R2 220.648. The current setup favors strength, but not an attractive fresh entry for a new long-term purchase at this exact level.
Recent analyst target increases across Truist, UBS, Baird, BofA, Barclays, Evercore ISI, and Jefferies show improving Street confidence. Q1 results beat expectations, and analysts highlighted strong organic volume growth, solid execution, and raised FY26 guidance. Hedge funds are aggressively buying, with buying up 1536.08% over the last quarter. No negative news was reported in the last week, which removes near-term event pressure.
The stock is technically overbought after a strong move, and short-term follow-through may be limited. The recent trend model suggests only modest downside probability over the next day/week/month, implying limited near-term reward from chasing the stock here. Options volume leans bearish on a put basis, and there is no fresh news catalyst in the past week to justify paying up aggressively at current levels. Insider activity is neutral, and there is no congress trading data to add confirmation.
Latest quarter: Q1 2026. The company reported a beat on sales and EPS, with organic volume growth standing out as the key strength. Management raised FY26 guidance after the quarter, which signals improving revenue and earnings momentum. While the full financial snapshot is unavailable, the available quarter commentary indicates healthy growth trends rather than deterioration.
Wall Street sentiment is constructive but not euphoric. Several analysts raised price targets after Q1, with targets ranging roughly from $220 to $245. The ratings are mixed: some Hold/Neutral/In Line views remain, but there are also Buy and Overweight calls from BofA, Barclays, and Jefferies. Pros: strong Q1 beat, raised guidance, volume growth momentum, and upside to estimates. Cons: some firms still view it as fairly valued or only in line, which suggests the street sees upside but not a screaming bargain.
